{"id":"W4416391870","doi":"10.1016/j.annonc.2025.09.107","title":"LBA91 Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary","funders":"Johnson and Johnson","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Homologous chromosome; Abiraterone; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001502199,0.001701804,0.002060112,0.0004787682,0.0004302035,0.001006924,0.0008329275,0.001456003,0.01381526],"category_scores_gemma":[0.001892747,0.0005119799,0.00300902,0.0004034073,0.0007785673,0.0008524022,0.000552192,0.003942033,0.00166334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004928138,"about_ca_system_score_gemma":0.0006993901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006830895,"about_ca_topic_score_gemma":0.001245382,"domain_scores_codex":[0.9992213,0.0004545962,0.00004135836,0.0001254098,0.00006259416,0.0000947979],"domain_scores_gemma":[0.9991556,0.0002548962,0.0002531027,0.00006521624,0.00005611557,0.000215026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9711071,0.002150878,0.0006162371,0.0007813728,0.001730329,0.00003340085,0.00001949404,0.0004366578,0.002464748,0.0001737494,0.001941355,0.01854472],"study_design_scores_gemma":[0.9454293,0.04682823,0.003634867,0.00006309644,0.001514378,0.0000569385,0.00001800519,0.0004298081,0.0003995676,0.0002627374,0.001343914,0.00001926454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9458891,0.01794893,0.002214587,0.002136379,0.001230188,0.005494428,0.01065339,0.0005570533,0.01387584],"genre_scores_gemma":[0.9716694,0.00407098,0.002614968,0.002518873,0.0006841181,0.004860518,0.006118122,0.0000684461,0.007394647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01381526,"threshold_uncertainty_score":0.04621661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04931411748077925,"score_gpt":0.4007666378702927,"score_spread":0.3514525203895135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}